Metabolic responses to monocomponent human insulin infusions in normal subjects and patients with liver and endocrine disease.
Hypoglycaemic and growth hormone responses were studied at different steady-state plasma insulin concentrations during a graded infusion of monocomponent human insulin. The control group consisted of ten volunteer subjects. The other groups studied included women taking oral contraceptives and patients with obesity, thyrotoxicosis, myxoedema, acromegaly, diabetes mellitus (moderate and severe) and liver disease. The hypoglycaemic response was measured in two ways: (i) the percentage reduction in plasma glucose below basal, and (ii) the rate of fall of plasma glucose (Kg-%/min). Insulin sensitivity was greatest in the normal subjects and in the other groups decreased in the order thyrotoxicosis greater than oral contraceptive greater than obesity greater than myxoedema greater than acromegaly greater than liver disease. Insulin sensitivity was difficult to assess in the diabetic patients because basal plasma glucose concentrations were elevated. At any given insulin concentration, the diabetics metabolized approximately the same amount of glucose as the normal subjects but the fact that this rate of glucose turnover occurred at higher plasma glucose concentrations probably indicated insulin resistance. Within each group Kg at each dose level of insulin correlated with the steady state plasma insulin concentration during the same infusion period. Diminishing sensitivity to insulin was reflected in an increasing fasting plasma insulin and insulin/glucose ratio except in patients with diabetes. GH responses to insulin infusion in normal subjects reflected the pattern of fall of plasma glucose. In the diabetic patients GH secretion appeared to be related to the infusion of insulin and occurred before plasma glucose had fallen to hypoglycaemic levels. GH secretory patterns were within normal limits in women taking oral contraceptives and in seven of eleven patients with liver disease but were impaired in three of seven patients with thyrotoxicosis and four of five patients with myxoedema. Four obese patients had a markedly delayed but eventually normal GH response.
D000172:Acromegaly / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003278:Contraceptives, Oral, Hormonal; D003920:Diabetes Mellitus / Q000378:metabolism; D004700:Endocrine System Diseases / Q000378:metabolism*; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D006980:Hyperthyroidism / Q000378:metabolism; D007263:Infusions, Parenteral; D007328:Insulin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009230:Myxedema / Q000378:metabolism; D009765:Obesity / Q000378:metabolism; D011863:Radioimmunoassay
D001786:Blood Glucose; D003278:Contraceptives, Oral, Hormonal; D007328:Insulin; D013006:Growth Hormone